The Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development organization. We discover, develop, and deliver treatments for neglected patients around the world. Our treatments are affordable and patient-friendly – and have already saved millions of lives.

We are researching new treatments for people living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, hepatitis C, and dengue. Together with our partners, we are working on over 40 projects, including more than 20 new chemical entities. We are also running over 20 clinical trials.

When the medical humanitarian organization Médecins Sans Frontières (MSF) won the Nobel Peace Prize in 1999, they dedicated a portion of the award to addressing this fatal imbalance and exploring a new, alternative, not-for-profit model for developing drugs for neglected patients. As a result in 2003, MSF, the World Health Organization, and five international research institutions founded DNDi.

Health Care

Life Sciences

Non Profit

Pharmaceutical

Research

Drugs for Neglected Diseases initiative - DNDi

Dr Luis Pizarro

Dominique Junod Moser

Pascal Carpentier

Wendy Keller

James Arkinstall

Ilan Moss

Phoutthasone Bouppha

Laurence Vielfaure

Nathalie Strub Wourgaft

Melchias Mukendi Ilunga

Clinical Research and Development Team

Communications and External Relations

Finance Team

Management and Director Team

Management and Consulting

Pharmaceutical and Drug Development

Human Resources Team

Teams at Drugs for Neglected Diseases initiative - DNDi